Hematologic and hemostatic tests are important and indispensable for diagnosing
any kind of hematologic disease. Recent advances in hematologic tests are
seen in automation of the blood cell counts and morphological analyses
that are required for diagnosing hematologic diseases, and in the accumulation
and availability of genetic and chromosomal examinations related to their
diagnosis. Although hemostatic tests used to be mainly aimed at checking
bleeding tendency, they are now being directed toward diagnosing thrombotic
tendency.
Medical expenses have hardly been increased in past revisions of reimbursement schedules for medical services, which has driven hospital management into an even tighter corner. In the field of laboratory examination, test fees were heavily slashed and calculated on an all-inclusive basis, forcing budgetary restrictions on the management of test laboratories.
I discuss the medical reimbursement for hematologic and hemostatic tests, focusing on the fiscal 2002 revision of the medical service fee schedule implemented in April.
[Rinsho Byori 50 : 786`790, 2002 ]
*Department of Clinical Pathology, Koshigaya Hospital, Dokkyo University School of Medicine, Koshi-gaya 343-8555
yKey Wordszhematologic and hemostatic tests(twIΈ)Chealth insurance reimbursement revision (fΓρVόθ)Cmedical reimbursement(Ϋ―Ώ)
*ΰΥ¦γΘεwzJa@Υ°Έ(§343-8555 zJsμzJ2-1-50)
E-mail :shime@dokkyomed.ac.jp